Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effectiveness, safety, and tolerability of 3
anti-HIV combination treatments that do not use protease inhibitors (PIs).
The current rule for starting treatment of HIV infection is to combine members from different
classes of anti-HIV drugs, such as 2 nucleoside reverse transcriptase inhibitors (NRTIs) and
either a PI or a nonnucleoside reverse transcriptase inhibitor (NNRTI). However, these
combinations can be complicated and difficult to take, can cause a number of side effects,
and may become ineffective. Combinations that are simpler, better tolerated, and more
effective are needed. Because PIs can cause long-term side effects and because HIV can become
resistant to many of them at the same time, anti-HIV combination treatments that do not use
PIs are being tested.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Abacavir Atazanavir Sulfate Didanosine Dideoxynucleosides Efavirenz HIV Protease Inhibitors Lamivudine Lamivudine, zidovudine drug combination Nevirapine Protease Inhibitors Stavudine Zidovudine